



WHAT DO THESE RESULTS MEAN FOR INDIVIDUALS WITH LOW BODY SURFACE AREA, MODERATE PSORIASIS?

The study showed that treatment with guselkumab helped improve nail psoriasis and psoriatic arthritis symptoms over 48 weeks. Participants with nail psoriasis saw significant improvement in their nail disease, and those with psoriatic arthritis experienced meaningful improvements in joint disease.



WHAT IS THE PURPOSE OF THIS STUDY?

- The purpose of the study is to evaluate the effectiveness and safety of **guselkumab** in treating people with **nail psoriasis** and those with **psoriatic arthritis** over a period of 48 weeks



WHO PARTICIPATED IN THE STUDY AND HOW WAS IT CONDUCTED?

- The study involved 338 patients with psoriasis who were randomly divided into two groups. One group received **guselkumab (GUS)**, and the other received **placebo (PBO)**. The treatment lasted for 48 weeks, with follow-up until Week 56.

SPECTREM Study Participants

SPECTREM enrolled people with **moderate plaque psoriasis** affecting **2-15%** of their total **body surface area**, with lesions affecting ≥ 1 high-impact site (scalp, face, skin folds, or genitals) that had failed ≥ 1 topical therapy




Numbers of participants:

225 GUS

113 PBO

Baseline Characteristics



GUS, guselkumab; Napsi, Nail Psoriasis Severity Index; PBO, placebo; PsA, psoriatic arthritis; PsAID-12, 12-Item Psoriatic Arthritis Impact of Disease questionnaire; PsO, psoriasis.

SPECTREM: Guselkumab Impact on Nail Psoriasis and Psoriatic Arthritis Through Week 48 in Participants With Low BSA, Moderate Psoriasis


Alice B. Gottlieb,¹ Joseph F. Merola,¹ Kim A. Papp,^{2,3} Marni Wiseman,^{4,5} Wei Jing Loo,⁶ Joe K. Tung,⁷ Theodore Alkousakis,⁸ Daphne Chan,⁸ Soumya D. Chakravarty,^{8,9} Jenny Jeyarajah,⁸ Richard G. Langley¹⁰

¹UT Southwestern Medical Center, Dallas, TX, USA; ²Alliance Clinical Trials and Probiy Medical Research, Waterloo, ON, Canada; ³University of Toronto, Toronto, ON, Canada; ⁴SkinWise Dermatology, MB, Canada; ⁵University of Manitoba, Winnipeg, MB, Canada; ⁶DermEffects, London, ON, Canada; ⁷University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ⁸Johnson & Johnson, Horsham and Spring House, PA, USA; ⁹Drexel University College of Medicine, Philadelphia, PA, USA; ¹⁰Dalhousie University, Halifax, NS, Canada




WHAT WERE THE RESULTS?

The study showed that **guselkumab** was well tolerated and provided **meaningful improvements** in **nail psoriasis** and **psoriatic arthritis**.



People with nail psoriasis showed steady nail improvement over time with GUS treatment, with much clearer nails by Week 48



People with psoriatic arthritis who took GUS had meaningful improvements starting at Week 8. These improvements were maintained through Week 48.

Glossary of terms

Guselkumab (GUS)	An anti-IL-23p19 monoclonal antibody used to treat psoriasis	Psoriasis (PsO)	A chronic skin condition characterized by red or purple, itchy, and scaly plaques	Nail Psoriasis Severity Index (Napsi)	A tool used to assess and grade the severity of nail bed and nail matrix psoriasis
Placebo (PBO)	A substance with no therapeutic effect used as a control	Psoriatic Arthritis (PsA)	A disease that causes joint pain, stiffness, and swelling in people with psoriasis	12-Item Psoriatic Arthritis Impact of Disease Questionnaire (PsAID-12)	A tool used to assess the impact of psoriatic arthritis on a patient's life



Scan the QR code for the full poster